About 200 reports

  • KEY UPDATES TO ANTI-INTERLEUKIN INHIBITOR MARKET DYNAMICS
  • SUMMARY TREMFYA TO DRIVE COMPETITION AMONG THE INTERLEUKIN INHIBITORS

Crohn’s Disease: Dynamic Market Forecast to 2026 Summary 2016 sales for the Crohn’s disease market is estimated to be approximately $9.0 billion across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), and Japan. Based on insights...

  • Biological Therapy
  • United States
  • World
  • Forecast
  • RedHill Biopharma Ltd.
  • MERCK
  • LONZA

LONZA: OPPORTUNITY ASSESSMENT Opportunity Assessment Merck delivers novel health solutions through its prescription medicines, biologic therapies, and consumer care products.

  • Biological Therapy
  • World
  • Forecast
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Company Analysis and Positioning
  • 5.1.7 THERAPEUTIC SOLUTIONS INTERNATIONAL INC.

ArunA has one product listed in its pipeline, the biologic therapy AB-##.

  • Biological Therapy
  • Cell Therapy
  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • 6 Global Cancer Biological Therapy Market, By Type
  • MARKET DYNAMICS FOR GLOBAL CANCER BIOLOGICAL THERAPY MARKET

Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. There are many biological therapies that have been approved and being used by various cancer...

  • Biological Therapy
  • World
  • Forecast
  • Market Size
  • Pfizer Inc.
  • Date

Glybera approved in Germany in 2015 for the treatment of rare blood condition with gene therapy costs about atleast $## million per treatment.

  • Biological Therapy
  • World
  • Market Size
  • Eppendorf AG
  • GE Healthcare Limited

Psoriatic arthritis

4385 5000 3900
  • US PSORIATIC ARTHRITIS TREATMENT RATE AND USAGE OF BIOLOGIC THERAPIES, BY DISEASE SEVERITY AND LINE OF THERAPY
  • ITALY PSORIATIC ARTHRITIS TREATMENT RATE AND USAGE OF BIOLOGIC THERAPIES, BY DISEASE SEVERITY AND LINE OF THERAPY

Humira and Enbrel will remain the dominant therapies in psoriatic arthritis (PsA), despite significant pressure from the launch of biosimilars. This report addresses the following questions: - To what extent will the launch of cheaper biosimilars affect sales of the longstanding tumor necrosis factor (TNF)-alpha inhibitors? -...

  • Biological Therapy
  • Amgen Inc.
  • Celgene Corporation
  • Johnson & Johnson
  • Novartis AG

The application of biosimilars in blood disease treatment is one of the highest revenue generating segment owing to the high-priced reference biologics and frequent application.

  • Biological Therapy
  • Biopharmaceutical
  • Biosimilar
  • Generic Drug
  • Pharmaceutical
  • Immunotherapy Drugs Sales Volume

Shanghai Institute of Red-Green Photosensitizers is the third largest producer and its ## million Yuan sales volume occupied ##. ##% of the total photodynamic therapy drugs sales volume.

  • Biological Therapy
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Changchun ChangSheng Gene Pharmaceutical Co., Ltd.
  • INCREASING FOCUS ON MULTIDISCIPLINARY CANCER CARE

The multi-modality treatment of cancer may include surgery, chemotherapy, biological therapy, or radiation therapy.

  • Biological Therapy
  • Forecast
  • Carl Zeiss Meditec AG
  • Eckert & Ziegler AG
  • Varian Medical Systems, Inc.

Whether they would be willing to sacrifice any benefit in exacerbation reduction for improved secondary considerations (such as FEV-## asthma control scores and ACQ-## asthma control scores) in a typical severe asthma patient being treated with a biologic therapy?

  • Asthma
  • Biological Therapy
  • Therapy
  • United States
  • Forecast

Biologics: Targets and Therapy; ##(##): ##-##.

  • Biological Therapy
  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Vaccine

Chemotherapy may be used alone or with RT or a biological therapy.

  • Biological Therapy
  • Cancer
  • Leukemia
  • Monoclonal Antibody
  • Therapy
  • PROVIDES A SWOT ANALYSIS OF OTHER BIOLOGIC THERAPIES (CAMPATH/LEMTRADA AND RITUXAN).
  • EFFICACY OF OTHER BIOLOGIC THERAPIES (CAMPATH/LEMTRADA AND RITUXAN) IN GVHD

Opportunity Analyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2023 Summary The main drivers of growth in graft versus host disease over the 2013-2023 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label...

  • Biological Therapy
  • Athersys, Inc.
  • Fresenius Group
  • GlobalData's company
  • Soligenix, Inc.
  • 2.1 TYPES OF STEM CELLS

They were asked to rank seven therapy areas according to the number of marketed therapies these would experience compared to one another (with ## having the lowest number of marketed therapies and ## the highest).

  • Biological Therapy
  • Cynata Therapeutics Limited
  • Mesoblast Limited
  • NuVasive, Inc.
  • Orthofix International N.V.

Gene therapy is emerging as one of the most exciting approaches for the treatment of ovarian cancer.

  • Biological Therapy
  • United States
  • Advantagene, Inc.
  • Celsion Corporation
  • Takara Bio Inc.
  • MARKET OVERVIEW

In Europe, the EC is one of the governmental organization that funds for biologicals research and development.

  • Biological Therapy
  • Biogen Idec Inc.
  • Novo Nordisk Group
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • 7.3.2. HISTORY OF DEVELOPMENT AND APPROVAL
  • 16. INTERVIEW TRANSCRIPTS

FIGURE ##. ## PRESENTS THE MOST PROMINENT VIRAL VECTORS THAT ARE BEING UTILIZED FOR DEVELOPING GENE THERAPIES TARGETING VARIOUS ONCOLOGICAL INDICATIONS. ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Biological Therapy
  • North America
  • United States
  • Company
  • Market Size

CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY CAR-T CELL THERAPIES FORM ONE OF THE MAJOR ARMS OF THE EXPERIMENTAL BIOLOGICAL ANTI-CANCER THERAPIES IN THE PHARMACEUTICAL MARKET.

  • Biological Therapy
  • China
  • Celgene Corporation
  • Juno Therapeutics Inc.
  • Novartis AG
  • IN NORTH AMERICA

IT CURRENTLY OPERATES AS ONE OF THE WHOLLY OWNED SUBSIDIARIES OF COBRA BIOLOGICS HOLDING.

  • Biological Therapy
  • United States
  • Market Size
  • Lonza Group Ltd
  • Sanofi S.A.
  • 4) Cancer Gene Therapy in the 8MM: History and Current Landscape

I think in terms of its biological potential, treatment potential, I think it is very, very big in other cancers.

  • Biological Therapy
  • Biotechnology
  • Gene Therapy
  • Therapy
  • United States

The three main technologies used in regenerative medicine are small molecules and biologics, gene therapy, and cell therapy.

  • Biological Therapy
  • Biotechnology
  • Molecular Biology
  • Tissue Engineering
  • Japan

SAMSUNG BIOLOGICS' PLANT ### CAME INTO OPERATION IN MAY 2011.

  • Biological Therapy
  • North America
  • United States
  • World
  • Biologics, Inc.

OTHER BIOLOGICS INCLUDE GENE THERAPIES, FUSION PROTEINS, UNSPECIFIED BIOLOGICAL MOLECULES INCLUDING IMETELSTAT (PHASE III), ABT-## (PHASE I) AND AMC## (PHASE I).

  • Biological Therapy
  • North America
  • United States
  • AstraZeneca PLC
  • Novartis AG

Leucotropin is a highly purified preparation of a monomeric, biologically active molecule.

  • Biological Therapy
  • Clinical Trial
  • Hospital
  • Lymphoma
  • Specialty Hospital

THESE TWO TRIALS WERE DESIGNED WITH ONE YEAR TREATMENT DURATION.

  • Biological Therapy
  • Biopharmaceutical
  • Biosimilar
  • Generic Drug
  • Pharmaceutical
  • IMCGP100: CURRENT STATUS OF DEVELOPMENT
  • highlights the forecasted growth of the overall CAR-T cells market spanning

NOVEL TREATMENTS FORM ANOTHER ARM OF THE AVAILABLE THERAPIES WHICH INCLUDES THE BIOLOGIC THERAPY.

  • Biological Therapy
  • North America
  • United States
  • Juno Therapeutics Inc.
  • Kite Pharma, Inc.

It is comprised of the delivery of a therapeutic gene, protein Phosphatase-## Inhibitor-## (I- ##) with the use of Biological NanoParticles (BNPs) and the Self-Complementary Vector Technology.

  • Biological Therapy
  • Bioheart, Inc.
  • Celladon Corporation
  • GlaxoSmithKline plc
  • Juventas Therapeutics, Inc.

" Based on those results, we will determine whether we will investigate this biologic therapy in a longer study, or perhaps consider studying a combination therapy that involves more than one biologic therapy. "

  • Biological Therapy
  • Leukemia
  • Pathology
  • Pharmaceutical
  • Therapy

SMC restriction: for use in patients in whom other non-biologic systemic treatments (methotrexate, ciclosporin and acitretin) are not appropriate or have failed and who are considered unsuitable for biologic therapy given their current disease state or personal pr

  • Autoimmune Disease
  • Biological Therapy
  • Clinical Trial
  • Dermatological Condition
  • Monoclonal Antibody

Patients entering the study will not have received any previous approved biological therapies for the treatment of HS.

  • Biological Therapy
  • Chronic Disease
  • Therapy
  • United States
  • Product Initiative